TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer

Completed · Not applicable

Conditions studied: Bladder Carcinoma

In brief

This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer. TracelT hydrogel marks the location of a bladder tumor and makes it more visible during imaging tests. Using TracelT hydrogel tissue marker may help doctors learn more about tumor location and altering radiation dosage for bladder cancer.

Key facts

Study ID

NCT03125226

Run by

University of Washington

People needed

12

Starts

2017-10-05

Expected to finish

2020-05-18

Last updated by the study team

2021-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed malignancy of the bladder
• No prior cystectomy
• Treatment plan for bladder must include at least 4 weeks of daily radiation treatment (most patients will receive chemotherapy concurrent with radiation, but this is not required for trial enrollment)
• Patient must undergo TraceIT hydrogel placement within 8 weeks prior to starting radiation therapy for bladder cancer
• Participants must have a complete history and physical examination within 60 days of study entry
• Participants must be able to provide informed consent for treatment and trial participation
• No restrictions on prior treatment to be eligible

You may not qualify if…

• Prior cystectomy
• Unable to have TraceIT hydrogel placement < 8 weeks prior to beginning radiation treatment
• Treatment for metastatic bladder cancer

Where it is running

• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.